Vertex Pharmaceuticals Incorporated re-iterated earnings guidance for the full year 2024. For the period, Company expects product revenue guidance of $10.55 to $10.75 billion.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
450.8 USD | +0.73% | +2.31% | +10.79% |
May. 22 | Vertex Pharmaceuticals Insider Sold Shares Worth $6,795,294, According to a Recent SEC Filing | MT |
May. 21 | ADDvise Group’s Axelerist Bags $1.4 Million Order for Medical, Lab Equipment | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+10.79% | 115B | |
+11.65% | 106B | |
-6.20% | 24.69B | |
-2.33% | 21.97B | |
-6.03% | 19.27B | |
-13.41% | 17.56B | |
-40.50% | 17.32B | |
+6.64% | 14.03B | |
+31.84% | 12.13B | |
-34.35% | 7.77B |
- Stock Market
- Equities
- VRTX Stock
- News Vertex Pharmaceuticals Incorporated
- Vertex Pharmaceuticals Incorporated Re-Iterates Earnings Guidance for the Full Year 2024